⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965337 | 0.98 | — | — | |
| SCHEMBL583649 | 0.98 | — | — | |
| SCHEMBL6476990 | 0.98 | — | — | |
| Water SCHEMBL6244435 | 0.97 | — | — | |
| SCHEMBL361549 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL3021166 | 0.92 | — | — | |
| SCHEMBL646408 | 0.90 | EPHX1 (0.40) | — | |
| SCHEMBL6360303 | 0.87 | CHRM2 (0.37) | — | |
| SCHEMBL27514912 | 0.87 | — | — | |
| SCHEMBL27510109 | 0.86 | EPHX1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378209-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20230157998-A1 | Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019 | PFIZER INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4114384-A1 | METHODS OF INHIBITING SARS-COV-2 REPLICATION AND TREATING CORONAVIRUS DISEASE 2019 | Pfizer Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220332690-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2022-10-20 | — | — | US | disclosed |
| CN-112341446-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-112341440-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11312693-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2022-04-26 | — | — | US | disclosed |
| WO-2021176369-A1 | METHODS OF INHIBITING SARS-COV-2 REPLICATION AND TREATING CORONAVIRUS DISEASE 2019 | PFIZER INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021027722-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| CN-1150206-C | Bradykinin antagonist peptides containing N-substituted glycines | — | 2004-05-19 | — | — | CN | disclosed |
| CN-1441806-A | Macrocyclic NS 3-serine protease inhibitors of hepatitis C virus comprising an N-ring P2 moiety | SCHERING CORP (US) | 2003-09-10 | — | — | CN | disclosed |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | SUNESIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| EP-1289972-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-5700779-A | ALLEVIATING PAIN, ASTHMA, INFLAMMATION, CEREBRAL EDEMA, CARDIOVASCULAR DYSFUNCTION | CORTECH, INC. (US) | 1997-12-23 | — | — | US | disclosed |